Global Narcolepsy Therapeutics Market 2023-2029
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global narcolepsy therapeutics market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors approaches.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the indication, product, therapeutics, and region. The global market for narcolepsy therapeutics can be segmented by indication: type 1 narcolepsy, type 2 narcolepsy, secondary narcolepsy. Among these, the type 1 narcolepsy segment was accounted for the highest revenue generator in 2022. Narcolepsy therapeutics market is further segmented by product: commercialized products, pipeline products. The commercialized products segment is estimated to account for the largest share of the global narcolepsy therapeutics market. Based on therapeutics, the narcolepsy therapeutics market is segmented into: central nervous system stimulants, norepinephrine reuptake inhibitor, histamine-3 (H3) receptor antagonist/inverse agonist. The central nervous system stimulants segment held the largest share of the global narcolepsy therapeutics market in 2022 and is anticipated to hold its share during the forecast period. On the basis of region, the narcolepsy therapeutics market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. In 2022, North America made up the largest share of revenue generated by the narcolepsy therapeutics market.
The commercialized products market is further segmented into Xywav, Sunosi, Wakix. The Xywav segment captured the largest share of the market in 2022 and is expected to maintain its dominance during the forecast period.
Market Segmentation
By indication: type 1 narcolepsy, type 2 narcolepsy, secondary narcolepsy
By product: commercialized products, pipeline products
By therapeutics: central nervous system stimulants, norepinephrine reuptake inhibitor, histamine-3 (H3) receptor antagonist/inverse agonist
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The market research report covers the analysis of key stake holders of the global narcolepsy therapeutics market. Some of the leading players profiled in the report include Avadel Pharmaceuticals plc, Axsome Therapeutics, Inc., Harmony Bioscience, LLC, Jazz Pharmaceuticals plc, NLS Pharmaceutics AG, Sumitomo Pharma Co., Ltd., Suven Life Sciences Limited, Takeda Pharmaceutical Co., Ltd., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Scope of the Report
To analyze and forecast the market size of the global narcolepsy therapeutics market.
To classify and forecast the global narcolepsy therapeutics market based on indication, product, therapeutics, region.
To identify drivers and challenges for the global narcolepsy therapeutics market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global narcolepsy therapeutics market.
To identify and analyze the profile of leading players operating in the global narcolepsy therapeutics market.
Why Choose This Report
Gain a reliable outlook of the global narcolepsy therapeutics market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience
PART 2. METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
Introduction
Drivers
Restraints
PART 5. MARKET BREAKDOWN BY INDICATION
Type 1 narcolepsy
Type 2 narcolepsy
Secondary narcolepsy
PART 6. MARKET BREAKDOWN BY PRODUCT
Commercialized products
Pipeline products
PART 7. MARKET BREAKDOWN BY THERAPEUTICS
Central nervous system stimulants
Norepinephrine reuptake inhibitor
Histamine-3 (H3) receptor antagonist/inverse agonist
PART 8. MARKET BREAKDOWN BY REGION
North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America
PART 9. KEY COMPANIES
Avadel Pharmaceuticals plc
Axsome Therapeutics, Inc.
Harmony Bioscience, LLC
Jazz Pharmaceuticals plc
NLS Pharmaceutics AG
Sumitomo Pharma Co., Ltd.
Suven Life Sciences Limited
Takeda Pharmaceutical Co., Ltd.
DISCLAIMER
Global Hepatitis Diagnostic Testing Markers Supplier Shares and Strategies Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals Blood Banks Commercial Labs POC Locations
Global Hepatitis Diagnostic Testing for 10 Markers: Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals, Blood Banks, Commercial Labs, POC Locations The
USD 7500 View Report2024 Global PSA Testing Market Supplier Shares and Strategies Volume and Sales Segment Forecasts Emerging Opportunities
2024 Global PSA Testing Market: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Opportunities This unique report from provides information and analysis not available from any
USD 2450 View ReportCOVID-19 Outbreak-Global Narcolepsy Drug Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
Narcolepsy is a neurological disorder characterized by the brains inability to control sleep/wakefulness cycles.The Narcolepsy Drug market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD
USD 3660 View ReportGlobal Narcolepsy Drug Market Report 2019, Competitive Landscape, Trends and Opportunities
The Narcolepsy Drug market has witnessed growth from USD XX million to USD XX million from 2014 to 2019. With the CAGR of X.X%, this market is estimated to reach
USD 2950 View ReportFill The Form For Sample Request